Oxidized low-density lipoprotein, a two-faced janus in coronary artery disease?

Biochemical Pharmacology

Volumn 56, Issue 3, 1998, Pages 279-284

  Parthasarathy, Sampath ^a   Santanam, Nalini ^a   Augé, Nathalie ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant; Atherosclerosis; Autoantibody; Biological effects; Low density lipoprotein; Oxidation

Indexed keywords

BUTYLCRESOL; CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHENYLENEDIAMINE DERIVATIVE; PHOSPHOLIPID; PROBUCOL; TOCOPHEROL;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031681382     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00074-4     Document Type: Article

References (48)

1. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage Implications for cholesterol deposition in atherosclerosis . Annu Rev Biochem. 52:1983;223-261.
2. Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL. The scavenger cell pathway for lipoprotein degradation Specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages . J Supramol Struct. 13:1980;67-81.
3. Kodama T, Reddy P, Kishimoto C, Krieger M. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci USA. 85:1988;9238-9242.
4. Stanton LW, White RT, Bryant CM, Protter AA, Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem. 267:1992;22446-22451.
5. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 268:1993;11811-11816.
6. Ottnad E, Parthasarathy S, Sambrano GR, Ramprasad MP, Quehenberger O, Kondratenko N, Green S, Steinberg D. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein Partial purification and role in recognition of oxidatively damaged cells . Proc Natl Acad Sci USA. 92:1995;1391-1395.
7. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells Recognition by receptors for acetylated low density lipoproteins . Proc Natl Acad Sci USA. 78:1981;6499-6503.
8. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA. 82:1985;3000-3004.
9. Parthasarathy S. Modified Lipoproteins in the Pathogenesis of Atherosclerosis. 1994;RG Landes Co, Austin TX.
10. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 77:1986;641-644.
11. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, Watson AD, Edwards PA, Lusis AJ. Pathogenesis of atherosclerosis. Am J Cardiol. 76:1995;18C-23C.
12. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 87:1990;5134-5138.
13. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 272:1997;13597-13607.
14. Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 262:1987;3603-3608.
15. Fong LG, Parthasarathy S, Witztum JL, Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res. 28:1987;1466-1477.
16. Fruebis J, Parthasarathy S, Steinberg D. Evidence for a concerted reaction between lipid hydroperoxides and polypeptides. Proc Natl Acad Sci USA. 89:1992;10588-10592.
17. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 10:1990;325-335.
18. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 98:1996;800-814.
19. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 98:1996;815-825.
20. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
21. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 15:1995;1569-1576.
22. Steinberg D, Parthasarathy S, Carew TE. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol. 62:1988;6B-12B.
23. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit . Proc Natl Acad Sci USA. 84:1987;7725-7729.
24. Cazzolato G, Avogaro P, Bittolo-Bon G. Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol Med. 11:1991;247-253.
25. Avogaro P, Bittolo Bon G, Cazzolato G. Isolation and partial characterization of an oxidized LDL in humans. Basic Life Sci. 49:1988;391-396.
26. Hodis HN, Kramsch DM, Avogaro P, Bittolo-Bon G, Cazzolato G, Hwang J, Peterson H, Sevanian A. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res. 35:1994;669-677.
27. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 37:1996;45-53.
28. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in the atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
29. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
30. Aznar-Salatti J, Bastida E, Buchanan MR, Castillo R, Ordinas A, Escolar G. Differential localization of von Willebrand factor, fibronectin and 13-HODE in human endothelial cell cultures. Histochemistry. 93:1990;507-511.
31. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA. 85:1988;9748-9752.
32. Reyftmann JP, Santus R, Maziere JC, Morliere P, Salmon S, Candide C, Maziere C, Haigle J. Sensitivity of tryptophan and related compounds to oxidation induced by lipid autoperoxidation. Application to human serum low- and high-density lipoproteins. Biochim Biophys Acta. 1042:1990;159-167.
33. Ling W, Lougheed M, Suzuki H, Buchan A, Kodama T, Steinbrecher UP. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II. J Clin Invest. 100:1997;244-252.
34. Fruebis J, Steinberg D, Dresel HA, Carew TE. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest. 94:1994;392-398.
35. Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans [published erratum appears in Arteriosclerosis 8: 857, 1988]. Arteriosclerosis. 8:1988;79-87.
36. Shimano H, Yamada N, Ishibashi S, Mokuno H, Mori N, Gotoda T, Harada K, Akanuma Y, Murase T, Yazaki Y, Takaku Y. Oxidation-labile subfraction of human plasma low density lipoprotein isolated by ion-exchange chromatography. J Lipid Res. 32:1993;763-773.
37. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 94:1993;350-356.
38. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 93:1992;189-199.
39. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 95:1995;2611-2619.
40. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 92:1995;821-825.
41. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 74:1984;1890-1894.
42. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA. 86:1989;1046-1050.
43. Thomas MJ, Rudel LL. Dietary fatty acids, low density lipoprotein composition and oxidation and primate atherosclerosis. J Nutr. 126:1996;1058S-1062S.
44. Rudel LL, Haines JL, Sawyer JK. Effects on plasma lipoproteins of monounsaturated, saturated, and polyunsaturated fatty acids in the diet of African green monkeys. J Lipid Res. 31:1990;1873-1882.
45. MacAuley D. Exercise, cardiovascular disease and lipids. Br J Clin Pract. 47:1993;323-327.
46. Laughlin MH, Simpson T, Sexton WL, Brown OR, Smith JK, Korthuis RJ. Skeletal muscle oxidative capacity, antioxidant enzymes, and exercise training. J Appl Physiol. 68:1990;2337-2343.
47. Goldfarb AH. Antioxidants Role of supplementation to prevent exercise-induced oxidative stress . Med Sci Sports Exerc. 25:1993;232-236.
48. Wetzstein CJ, Shern-Brewer RA, Santanam N, Green NR, White-Welkeley JE, Parthasarathy S. Does acute exercise affect the susceptibility of low density lipoprotein to oxidation? Free Radic Biol Med. 24:1998;679-682.